Member access

4-Traders Homepage  >  Shares  >  Nyse  >  AbbVie Inc    ABBV   US00287Y1091

ABBVIE INC (ABBV)

44
 SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
09/10/2014 09/11/2014 09/12/2014 09/15/2014 09/16/2014 Date
57.19(c) 57.85(c) 57.88(c) 57.93(c) 58.605 Last
8 740 253 9 943 954 15 556 226 8 632 657 6 891 022 Volume
+0.42% +1.15% +0.05% +0.09% +1.17% Change
More quotes
Company
AbbVie, Inc. is a research-based biopharmaceutical company. It engages in the discovery, development, manufacture and sale of a broad line of proprietary pharmaceutical products. The company's products are used to treat rheumatoid arthritis, psoriasis, Crohn's disease, HIV, cystic fibrosis... 
Sector
Pharmaceuticals
Calendar
10/24Earnings Release
Surperformance© rating of AbbVie Inc
Trading Rating : Investor Rating :
More about the company
Chart ABBVIE INC
Duration : Period :
AbbVie Inc Technical Analysis Chart | ABBV | US00287Y1091 | 4-Traders
Full-screen chart
Financials ($)
Sales 2014 19 611 M
EBIT 2014 6 843 M
Net income 2014 4 722 M
Debt 2014 4 781 M
Yield 2014 2,86%
Sales 2015 21 731 M
EBIT 2015 8 886 M
Net income 2015 6 011 M
Debt 2015 1 380 M
Yield 2015 3,11%
PER 2014 20,52
PER 2015 14,03
EV / Sales 2014 4,94x
EV / Sales 2015 4,31x
Capitalization 92 192 M
More Financials
Latest news on ABBVIE INC
2h ago Roche's $8 billion InterMune buy not a signal for more big deals
1d ago EU to decide on $52 billion AbbVie, Shire deal by Oct. 16
1d ago ABBVIE : Hynes Keller & Hernandez, LLC : Announces Investigation of World Accept..
1d ago ABBVIE : Assigned Patent
4d ago ABBVIE : Detailed Results from Biogen Idec and AbbVie’s Pivotal Phase 3 De..
5d ago ABBVIE : Announces Pivotal Phase 3 Data Evaluating Efficacy of HUMIRA® (adalimum..
6d ago INFINITY PHARMACEUTICALS : and AbbVie Announce Global Strategic Collaboration to..
09/09DJU.S. HOT STOCKS : Hot Stocks to Watch
09/09 ABBVIE : Grassley Comments on FTC Filing Complaint Against Rx Companies for Anti..
09/08 ABBVIE : FTC sues AbbVie, Teva over generic AndroGel
09/08 ABBVIE : Assigned Patent
09/05 ABBVIE : to Present at Morgan Stanley Global Healthcare Conference
More news
Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Technical analysis
Income Statement Evolution
AbbVie Inc : Income Statement Evolution
More Financials
EPS Revisions
AbbVie Inc : EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF